The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research.

Start Date01 Aug 2025

Sponsor / Collaborator-

JPRN-jRCT2031240116

/ SuspendedNot ApplicableIIT

A comparative use-result survey by test-negative case-control study for evaluation the effectiveness of FluMist intranasal spray in preventing influenza over time - A comparative use-result survey by test-negative case-control study for evaluation the effectiveness of FluMist intranasal spray in preventing influenza over time

Start Date01 Jan 2025

Sponsor / Collaborator-

NCT06501963

/ RecruitingPhase 4IIT

Revealing Protective Immunity to Influenza Using Systems Immunology

The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines.

Start Date14 Oct 2024

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

100 Translational Medicine associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

100 Patents (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

128

Literatures (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

01 Aug 2025·JOURNAL OF CONTROLLED RELEASE

Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9

Article

Author: Williamson, Grace L ; Staats, Herman F ; Lukesh, Nicole R ; Petrovsky, Nikolai ; Hendy, Dylan A ; Abraham, Mathew A ; Ashcraft, Kathleen A ; Ross, Ted M ; Bachelder, Eric M ; Landon, Chelsea D ; Heise, Mark T ; Murphy, Connor T ; Pena, Erik S ; Carlock, Michael ; Abraham, Soman N ; Ontiveros-Padilla, Luis ; Ainslie, Kristy M

Flumist is the only FDA-approved intranasal influenza vaccine. Although it has recently been approved for at-home use, it has significant limitations. These include reduced effectiveness in generating a protective immune response in patients with extensive influenza exposure, safety concerns due to its live attenuated virus formulation, and reduced efficacy due to viral drift/shift. To address this limitation, we have developed a nanocomplex comprised of a mast cell (MC) agonist and toll-like receptor 9 (TLR9) ligand to adjuvant a broadly acting influenza antigen. The newly reported MC agonist was identified by screening mastoparan-7 analogs for MC degranulation activity, which led to a more active peptide analog, MP12W. Positively charged MP12W spontaneously forms nanoparticulate complexes (NPs) with CpG 1826 that were then used to intranasally vaccinate mice with a computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) protein. The NPs were further optimized by substituting CpG 1826 with CpG 55.2, a TLR-9 agonist identified by machine learning to be more active in humans. MP12W-CpG 1826 NPs showed an increased pro-inflammatory response and decreased cytotoxicity in vitro compared to M7 complexes, translating into a safer profile in a model of increased hypersensitivity, collaborative cross mice 027 (CC027). Intranasal vaccination with this complex and broadly reactive HA resulted in higher mucosal antibody concentration and increased cytokine production with antigen recall. These responses were enhanced with MP12W-CpG 55.2 NP vaccination. MP12W-CpG NPs provided similar protection in an influenza challenge model. This study demonstrates the potential of this novel intranasal nanocomplex for vaccination.

01 Feb 2025·JOURNAL OF INFECTION AND CHEMOTHERAPY

The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study

Article

Author: Oe, Keiji ; Hayashi, Takuya ; Nakayama, Tetsuo ; Makino, Kentaro

BACKGROUND:

Vaccination is the primary method of preventing influenza infection and complications in young children. We evaluated the efficacy and safety of a single dose of MEDI3250 (intranasal, quadrivalent, live attenuated influenza vaccine) in healthy Japanese children during the 2016/17 influenza season.

METHODS:

In this multicenter, randomized, double-blind, phase 3 study (jRCT2080223345), participants aged 2-18 years received MEDI3250 or placebo (2:1), stratified by age (2-6 years, 7-18 years). The primary and secondary endpoints were the incidence of confirmed symptomatic onset of influenza caused by a circulating wild-type strain or by a vaccine-matched strain, respectively. Safety outcomes included the incidence of adverse events (AEs) and vaccine-related AEs.

RESULTS:

Overall, 910 participants received MEDI3250 (n = 608) or placebo (n = 302). For the primary endpoint (regardless of the influenza subtype), the incidence of influenza onset was 25.5 % (MEDI3250) and 35.9 % (placebo); relative risk reduction, 28.8 % (95 % confidence interval, 12.5 %, 42.0 %). For the secondary endpoint (vaccine-matched strain), the incidence was 10.9 % (MEDI3250) and 17.2 % (placebo); relative risk reduction, 36.6 % (95 % confidence interval, 6.5 %, 56.8 %). Solicited AEs occurred in 67.6 % (MEDI3250) and 63.6 % (placebo). Most events were mild; nasal discharge was most common (59.2 % [MEDI3250] and 52.6 % [placebo]). Unsolicited AEs occurred in 36.0 % (MEDI3250) and 33.1 % (placebo). The most common unsolicited vaccine-related AE was diarrhea (2.3 %, both groups).

CONCLUSIONS:

MEDI3250 had a greater preventive effect against influenza onset in Japanese children than placebo; no new safety signals were observed relative to previous clinical and post-marketing studies of MEDI3250.

01 Dec 2023·The Lancet. Child & adolescent health

Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial

Article

Author: Stensballe, Lone Graff ; Lund, Lars Christian ; Kildegaard, Helene ; Pottegård, Anton

BACKGROUND:

Scant evidence exists on the real-world effectiveness of quadrivalent live attenuated influenza vaccines (LAIV-4) in younger children. We aimed to assess the real-world effectiveness of LAIV-4 against influenza-related hospital contacts and admission and morbidity.

METHODS:

Using nationwide Danish health-care registries, we designed a cohort study that emulates a target trial, comparing LAIV-4 to no vaccination in children aged 2-6 years. Eligible children vaccinated from Oct 1, 2021, to Jan 15, 2022, were matched to unvaccinated controls in a 1:1 ratio according to demographic characteristics and risk groups for influenza, and followed-up until May 31, 2022. Primary study outcomes any hospital contact for influenza and influenza-related hospital admissions more than 12 h in duration, while hospital admission for respiratory tract infections, or for wheezing or asthma, and antibiotic prescriptions were evaluated as secondary outcomes. We estimated incidence rate ratios (IRRs) and 95% CIs using Poisson regression for each outcome. Vaccine effectiveness was calculated as 1 - IRR.

FINDINGS:

Among 308 520 Danish children aged 2-6 years, 95 434 vaccinated children were matched with 95 434 unvaccinated children who acted as controls. Receipt of LAIV-4 compared with no vaccination was associated with a reduced IRR of 0·36 (95% CI 0·27 to 0·46) and estimated vaccine effectiveness of 64·3% (53·6 to 72·6) against influenza-related hospital contacts (76 vs 210 events). The corresponding IRR and vaccine effectiveness against influenza-related hospital admissions were 0·63 (0·38 to 1·05) and 36·9% (-5·2 to 62·1; 24 vs 38 events), respectively. LAIV-4 was not associated with reductions in admission rates for respiratory tract infections (IRR 1·14, 95% CI 0·94 to 1·38), wheezing or asthma (1·04, 0·83 to 1·31), or antibiotic prescriptions for respiratory tract infections (0·97, 0·93 to 1·00). Vaccine effectiveness assessed across risk groups for influenza showed similar effectiveness in children with and without coexisting risk factors for severe influenza.

INTERPRETATION:

LAIV-4 offered moderate protection in younger children against influenza-related hospital contacts during a season dominated by influenza A(H3N2); however vaccination was not associated with reductions in secondary outcomes. This real-world study thereby supports trial evidence of moderate vaccine effectiveness of LAIV-4 against influenza-related outcomes when implementing broad vaccination schedules in younger children.

FUNDING:

Beckett-Fonden.

News (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

27 Sep 2024

·www.prnewswire.com

Weekly Recap: 13 Health Press Releases You Might Have Missed

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the first nasal spray flu vaccine, upcoming disease awareness campaigns and more. NEW YORK, Sept. 27, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Sept. 23-27, 2024. Photo provided by ASICS. FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration The U.S. Food and Drug Administration (FDA) approved FluMist for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. The vaccine is sprayed into the nose and has been used safely and effectively for many years. Nearly Two-Thirds of Americans Fear Medicare Will Not Be There When They Need It "Concerns about the future of Medicare are adding another layer of uncertainty for Americans as they consider how they'll manage health care costs in retirement," said Kristi Martin Rodriguez, senior vice president of the Nationwide Retirement Institute. "With high living costs already squeezing household budgets, many are worried about having enough saved to cover their long-term health care." Cardinal Health to Acquire Integrated Oncology Network, a Physician-Led Independent Community Oncology Network The transaction demonstrates Cardinal Health's continued investment in specialty and oncology, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states. ADHD Redefined: ADDitude Honors ADHD Empowerment Month with Groundbreaking Campaign Throughout October, ADDitude will highlight a new definition of ADHD each day, sharing inspiring stories of readers who have contributed their personal experiences. The campaign will also feature exclusive profiles of prominent figures in the ADHD community, including novelist Rebecca Makkai, stand-up comedian Rachel Feinstein, and illustrator Hayley Wall, who explain how ADHD shaped their creativity and careers. Halle Berry's Respin and Menopause Pioneer Joylux Announce Strategic Partnership to Advance Intimate Health & Wellness Halle Berry is a passionate advocate for women's health, especially concerning menopause. The collaboration marks a significant milestone for Respin and Joylux as they work together to destigmatize the taboo of intimate health with science-backed solutions that empower women to take control of their health. Hear Powerful Stories of Individuals Living with Familial Hypercholesterolemia in ABC's "Family Heartbeats Unmasked" The new campaign from the Association of Black Cardiologists (ABC) is dedicated to raising awareness about Familial Hypercholesterolemia (FH), a genetic condition that significantly increases the risk of early heart disease and is often underdiagnosed, especially in Black Americans and other minority populations. Flex Confirms Period Discs and Cups Are Free from Harmful Metals and PFAS Amid Concerns Over Toxic Chemicals in Tampons Flex announced that independent third-party lab testing confirmed all Flex menstrual discs and cups are free from harmful PFAS (forever chemicals), lead, arsenic, cadmium, and mercury. This follows the FDA's recent decision to investigate toxic metals found in tampons, fueling discussions about the need for more research and innovation in menstrual health. Brian Cox Warns the World About Workplace Mental Health Threat in PSA for ASICS In the PSA, Brian Cox plays the role of the world's scariest boss to highlight the silent threat to our mental health—the desk we work at every day. The PSA calls on office workers to put their mental health first by taking a Desk Break, a short movement break, during the working day. WebMD Announces 2024 Health Heroes: Visionaries Leveraging AI in Medicine "Artificial Intelligence is reshaping healthcare in profound ways, saving lives and improving patient outcomes," said Dr. John Whyte, Chief Medical Officer of WebMD. "This year's Health Heroes are leading the way in AI innovation, and we are honored to recognize their achievements." Bosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S. The partnership initiates a new era in hair loss treatment by introducing the first FDA-cleared fractional laser solution for hair loss to U.S. customers for the first time, potentially transforming the lives of millions of people affected by hair loss in the U.S. NYU Langone Health Forms New Partnership to Minimize Deaths from Extreme Heat Amid Rising Global Temperatures Project HEATWAVE (Heat Emergency Avoidance Technologies Working to Adapt to Vulnerabilities Equitably), according to its founders, will be the first-ever initiative to combine advanced climate modeling, public health analysis and policy, and medical and technology innovation to study and help reduce heat-related mortality due to climate change. October is Raynaud's Awareness Month Raynaud's phenomenon is a disorder that affects blood vessels, primarily in the fingers and toes, causing them to constrict in response to cold temperatures or stress. This loss of blood flow can result in episodes of numbness, tingling, and color changes in the affected areas. Seelos Therapeutics Announces the Signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to Evaluate SLS-002 for Treatment of PTSD "Approximately 13 million people in the U.S. live with PTSD and there have been no new drugs approved in the last two decades for people suffering the effects of PTSD," said Raj Mehra, Ph.D., Chief Executive Officer of Seelos. "I believe that the inclusion of SLS-002 in this study is due to the robust amount of anecdotal evidence that ketamine has the potential to be an effective therapeutic for the symptoms of PTSD and other related conditions." For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalVaccine

20 Sep 2024

·www.pharmaindustrial-india.com

FDA Approves Nasal Spray Influenza Vaccine for Caregiver Administration

The US Food and Drug Administration (US FDA) has approved FluMist for self- or caregiver-administration. FluMist is approved for preventing influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age. It is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a health care provider. "Today's approval of the first influenza vaccine for self- or caregiver administration provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Getting vaccinated each year is the best way to prevent influenza, which causes illness in a substantial proportion of the U.S. population every year and may result in serious complications, including hospitalization and death. This approval adds another option for vaccination against influenza disease and demonstrates the FDA's commitment to advancing public health." FluMist contains a weakened form of live influenza virus strains and is sprayed in the nose. A prescription is still required to receive FluMist. There are now two approved options for receiving FluMist. The vaccine may be administered by a health care provider in a healthcare setting (including a pharmacy) or it may be administered by the vaccine recipient or a caregiver who is 18 years of age or older. The most commonly reported side effects of FluMist are fever over 100°F in children 2 through 6 years of age, runny nose and nasal congestion in individuals 2 through 49 years of age and a sore throat in adults 18 through 49 years of age. For those interested in self- or caregiver-administration, the vaccine manufacturer plans to make the vaccine available through a third-party online pharmacy. Those who choose this option will complete a screening and eligibility assessment when they order FluMist. The third-party pharmacy determines eligibility based on the completed screening and, if it is determined that the intended vaccine recipient is eligible, the pharmacy writes the prescription and ships the vaccine to the address provided by the individual who placed the order. The vaccine can then be administered to the prescribed household member(s) at their convenience. Vaccine recipients and caregivers who administer FluMist will be sent the vaccine, the Prescribing Information, Information for Patients and their Caregivers and Instructions for Use. The Instructions for Use provides detailed instructions for storage, administration and disposal of FluMist. The FDA granted this approval of FluMist (Influenza Vaccine Live, Intranasal) to MedImmune LLC.

Drug ApprovalVaccine

20 Sep 2024

·www.drugs.com

FDA Approves First Flu Vaccine That Can Be Self-Administered at Home

FRIDAY, Sept. 20, 2024 -- On Friday, the U.S. Food and Drug Administration approved the FluMist nasal vaccine for self-administration at home. It is a "new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility, and accessibility for individuals and families," Peter Marks, M.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release. It has been a long time coming, however: MedImmune FluMist was first approved in 2003 for people ages 5 to 49 years to prevent flu, and then approval was extended to children ages 2 to 5 years in 2007. It is a nasal spritz that contains a weakened form of the live influenza virus. However, until now, it was always administered by a health care provider. A prescription will still be needed to get FluMist, the FDA said, and only individuals aged 18 years and older are authorized to administer it to themselves or a child in their care. "For those interested in self or caregiver administration, the vaccine manufacturer plans to make the vaccine available through a third-party online pharmacy," the FDA said. "Those who choose this option will complete a screening and eligibility assessment when they order FluMist." Friday's approval was based on a study "conducted with vaccine recipients and caregivers to evaluate whether the instructions for use were appropriately designed so that recipients and caregivers could safely and effectively use the vaccine," the FDA noted. Anyone who is prescribed FluMist will receive the vaccine as well as detailed instructions on how to administer, store, and dispose of the product. This approval of FluMist was granted to MedImmune. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalVaccine

100 Deals associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	European Union	AstraZeneca AB	04 Dec 2013
Influenza, Human	Iceland	AstraZeneca AB	04 Dec 2013
Influenza, Human	Liechtenstein	AstraZeneca AB	04 Dec 2013
Influenza, Human	Norway	AstraZeneca AB	04 Dec 2013
Influenza A virus infection	United States	MedImmune LLC	17 Jun 2003
Influenza B virus infection	United States	MedImmune LLC	17 Jun 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza-like symptoms	Phase 3	Japan	AstraZeneca PLC	01 Oct 2014
Chronic Disease	Phase 3	United States	MedImmune LLC	01 Aug 2009
Chickenpox	Phase 3	-	MedImmune LLC	01 Dec 2000
Measles	Phase 3	-	MedImmune LLC	01 Dec 2000
Mumps	Phase 3	-	MedImmune LLC	01 Dec 2000
Rubella	Phase 3	-	MedImmune LLC	01 Dec 2000
HIV Infections	Phase 2	United States	MedImmune LLC	01 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2019	Not Applicable	-	540	Flu vaccination (Patients on ICI)	cxyukantsp(ezduvgzicn) = ksohsffdzv rrlsxiuasd (xkmayxqflk )	-	26 May 2019
				Flu vaccination (Patients on non-ICI modalities)	cxyukantsp(ezduvgzicn) = umcjpmwwqf rrlsxiuasd (xkmayxqflk )
NCT03028974 (CTgov)	Phase 4	Influenza, Human	77	FluMist® (Group A: 2-4 yo LAIV4 (Return))	yqxiaopvga = banifvzaff lxyjmmhpdu (byslotepfh, wlubgipdmo - lytadicoxv) View more	-	14 Dec 2018
				Fluzone® (Group E: 6 - 23 Mos Old IIV4 (Single Yr))	ztbirxddoq = dtyfxkgytu uxpsucirzn (egyfyojdkh, nnpzfrcepq - ouvumvaxxl) View more
NCT03143101 (FluMist, CTgov)	Phase 4	Influenza, Human	200	FluMist trivalent (FluMist Trivalent (2015-2016))	ahjudnfitx = ezggoyayqg bzhnskbyvb (yyynravzlv, mukgzrxznz - hbjsqmefil) View more	-	11 Dec 2018
				FluMist Quadrivalent (FluMist Quadrivalent (2015-2016))	ahjudnfitx = rwtdtvxzea bzhnskbyvb (yyynravzlv, rncjwbnaen - ecjmyjwism) View more
NCT02474901 (QLAIV, CTgov)	Phase 2	HIV Infections \| Influenza, Human	101	Quadrivalent Live Attenuated Influenza Vaccine (QLAIV, HIV-infected)	ygjzqbfhtp = igwunsqkxf fgjlelpcxp (vbefyyejen, wyjuwqsxaq - acokxguvjb) View more	-	16 Oct 2017
				Quadrivalent Live Attenuated Influenza Vaccine (QLAIV, HIV-uninfected)	ygjzqbfhtp = jovlefnpjk fgjlelpcxp (vbefyyejen, artmcdplym - mmwnfrevfc) View more
NCT03028987 (CTgov)	Phase 4	Influenza, Human	10	FluMist® (LAIV Randomized)	jcuhdqgiht = pbxagndbeg gzkwhsqouu (yrrzidrubc, mcrmttjxqh - nkbjqitlqw) View more	-	12 Sep 2017
				Fluzone® (IIV4 Randomized)	jcuhdqgiht = lctrqcahic gzkwhsqouu (yrrzidrubc, fjybrbepyv - eskhbdnliv) View more
NCT01933048 (SNIF, CTgov)	Phase 4	Influenza, Human	1,077	FluMist (Healthcare Worker Administration)	ndyfqozhyt(eqvleodjdw) = afltsvepoi urmsrajkeu (htqhnovcmw, zbafnkxrgw - johejnvqjb) View more	-	12 Sep 2017
				FluMist (Self-Administration)	ndyfqozhyt(eqvleodjdw) = pvqzokkquu urmsrajkeu (htqhnovcmw, fnvzywmnpo - lagdpipjqy) View more
NCT02141581 (CTgov)	Phase 4	Influenza, Human	86	Fluzone	zstzucbcht = kskkhztciw soydsuseqm (wcpxdxpivc, rtvbeooaza - pnakrjiyrq) View more	-	11 May 2017
NCT03023709 (CTgov)	Phase 4	Influenza, Human	3	Fluzone® (Pilot Phase)	xzthmqerjg = yzrgdlelbd ymrmkfxpkz (vriyvklftd, pbikqgvhzf - xvauscfxkb)	-	10 May 2017
				FluMist® (Study Phase)	xzthmqerjg = pbrushhitj ymrmkfxpkz (vriyvklftd, jhhbqkvhfs - plgynaozwx)
NCT02133781 (CTgov)	Phase 4	Influenza, Human	51	Fluzone+FluMist (Age 8-17 Years (Identical Twins ))	cmkmrffoof = xozrshkwzm xaheiqgbda (gjzajsicwk, mnquompakf - nddfgmgyzo) View more	-	10 Mar 2017
				Fluzone (Age 18-30 Years (Non-twins))	cmkmrffoof = payhzrabef xaheiqgbda (gjzajsicwk, dktbvstgbw - dvibwikyam) View more
NCT03023683 (CTgov)	Phase 4	Influenza, Human	18	FluMist® (Group A: 2-8 yo Healthy Non-twins)	sjaihltghd = khquummnsm reejdwponl (cvmdmmhxpx, ziuljquuxi - pbpsmjjzbu) View more	-	09 Mar 2017
				FluMist® (Group B: 18-49 yo Healthy Non-twins)	sjaihltghd = ykpiinhcdr reejdwponl (cvmdmmhxpx, eqycvbjgjs - moxjxpsoyq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis